权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Epigenetic Regulation of MMP-13

MMP-13 的表观遗传调控

基本信息

批准号：
7495610
负责人：
MARY B GOLDRING
金额：
$ 18.44万
依托单位：
HOSPITAL FOR SPECIAL SURGERY
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-09-15 至 2010-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7495610
关键词：
Accounting Adherent Culture Binding Binding Sites Biological Assay Cartilage Cartilage Matrix Cells Chondrocytes Collagen Type II Condition DNA DNA Methylation Data Decitabine Degenerative polyarthritis Depth Disease Progression EMSA Endopeptidases Enhancers Enzymes Epigenetic Process Fracture Gene Expression Gene Expression Regulation Gene Silencing Genes Genetic Transcription Head Heart Histone Deacetylase Inhibitor Human In Vitro Individual Inflammatory Luciferases Matrix Metalloproteinases Mediating Methylation New York Nuclear Nuclear Extract Nucleic Acid Regulatory Sequences Pathology Patients Peptide Hydrolases Polymerase Chain Reaction Prevention Proliferating Promoter Regions RNA Regulation Reporter Sampling Severities Site Somatic Cell Source SssI methylase Structure of neck of femur Synovial Membrane TNFRSF5 gene Techniques Testing Time Transcription Coactivator Transcription Factor AP-1 Transcriptional Regulation Trichostatin A Validation activating transcription factor articular cartilage collagenase collagenase 3 cytokine demethylation experience expression vector in vitro Assay in vivo mRNA Expression oncostatin M p65 prevent promoter response transcription factor vector

项目摘要

DESCRIPTION (provided by applicant): A key feature of osteoarthritis (OA) is the erosion of articular cartilage, which is caused by degradative proteinases, such as matrix metalloproteinases (MMPs) and aggrecanases, which are produced abnormally by certain OA chondrocytes. Chondrocyte-dependent matrix-degrading activities lie at the heart of OA pathology and prevention may halt or slow down the inevitable progression of OA. This project will concentrate on the regulation of the gene encoding the major collagenase involved in OA, namely MMP-13. In vivo, gene expression is not only controlled by transcriptional activators and repressors, but also depends on the epigenetic DNA methylation of the promoter, which is the mechanism whereby genes that are never expressed by a somatic cell are permanently silenced. This study will be the first to take into account the DNA methylation status of the MMP-13 promoter to investigate regulation of expression of this gene in a manner that replicates what takes place in vivo. We will test the following hypothesis: MMP-13 promoter activity is determined by the interactions between DNA methylation status and transcription factor binding to cognate binding sites. Thus, the presence of methylation correlates, on the whole, with gene silencing by preventing the binding of some transcription factors. Specific aims are: 1) Determine the methylation status of all 14 CpG sites in the MMP-13 promoter in chondrocytes derived from non-OA, superficial and deep zones of OA patients, quantify mRNA expression and % methylation for selected CpG sites. 2) Investigate the effects of inflammatory cytokines and a demethylation agent on MMP-13 expression and methylation status. 3) Compare the effects of transcription factors on MMP-13 promoter activity in non-methylated and methylated promoter constructs. 4) Investigate specific binding of transcription factors to the MMP-13 promoter in normal vs cytokine-induced chondrocytes. After providing complete in vivo data regarding the changes in methylation status in OA, we will determine how the methylation status of normal chondrocytes is changed by inflammatory cytokines. Our sub-hypothesis is that these cytokines will initiate a demethylation of the MMP-13 promoter, thereby increasing accessibility to transcription factors and thus transcription of MMP-13. In the promoter construct studies, we will focus initially on transcription factors that are known to regulate MMP-13 promoter activity, including ETS factors, AP-1, Runx2 and NFkB. Our sub- hypothesis is that DNA methylation will prevent binding of some, but not all, transcription factors. We will then investigate which transcription factors are actually bound to the MMP-13 promoters in MMP-13 expressing vs non-expressing cells in cotransfections using non-methylated and methylated MMP-13 promoter constructs and in EMSA and ChIP assays. This will allow us to correlate functional responses with the proximity of CpG sites and methylation status. The first two aims will be investigated by the Co-PI in Southampton, where previous experience in the techniques exists. The second two aims build on the experience of the PI with respect to the transcriptional regulation. Previous findings by the Southampton group indicate that demethylation underlies the abnormal MMP-13 expression in OA. The proposed studies will advance considerably our understanding about the importance of DNA methylation in the pathology of OA.

描述（由申请人提供）：骨关节炎（OA）的一个关键特征是关节软骨的侵蚀，这是由某些OA软骨细胞异常产生的降解性蛋白酶（如基质金属蛋白酶（MMP）和聚集蛋白聚糖酶）引起的。软骨细胞依赖性基质降解活动是OA病理学的核心，预防可能会阻止或减缓OA的不可避免的进展。该项目将集中于编码OA中涉及的主要胶原酶（即MMP-13）的基因的调控。在体内，基因表达不仅受转录激活子和阻遏子控制，而且还取决于启动子的表观遗传DNA甲基化，这是体细胞从未表达的基因永久沉默的机制。这项研究将是第一个考虑到MMP-13启动子的DNA甲基化状态，以复制体内发生的方式研究该基因表达的调控。我们将测试以下假设：MMP-13启动子活性是由DNA甲基化状态和转录因子结合到同源结合位点之间的相互作用决定的。因此，总的来说，甲基化的存在通过阻止某些转录因子的结合而与基因沉默相关。具体目标是：1）测定源自非OA、OA患者的浅表区和深部区的软骨细胞中MMP-13启动子中所有14个CpG位点的甲基化状态，定量所选CpG位点的mRNA表达和甲基化%。2)研究炎性细胞因子和去甲基化剂对MMP-13表达和甲基化状态的影响。3)比较转录因子对非甲基化和甲基化启动子构建体中MMP-13启动子活性的影响。4)研究正常软骨细胞与苦参碱诱导的软骨细胞中转录因子与MMP-13启动子的特异性结合。在提供了完整的关于OA甲基化状态变化的体内数据后，我们将确定炎症细胞因子如何改变正常软骨细胞的甲基化状态。我们的亚假设是这些细胞因子将启动MMP-13启动子的去甲基化，从而增加转录因子的可及性，从而增加MMP-13的转录。在启动子构建体研究中，我们将首先关注已知调节MMP-13启动子活性的转录因子，包括ETS因子、AP-1、Runx 2和NFkB。我们的子假设是DNA甲基化会阻止某些但不是全部转录因子的结合.然后，我们将研究哪些转录因子实际上结合到MMP-13启动子在MMP-13表达与非表达细胞在共转染使用非甲基化和甲基化MMP-13启动子构建体和在EMSA和ChIP测定。这将使我们能够将功能反应与CpG位点的接近度和甲基化状态相关联。前两个目标将由南安普顿的Co-PI进行调查，那里有以前的技术经验。后两个目标建立在PI关于转录调控的经验上。南安普顿研究小组先前的发现表明，去甲基化是OA中MMP-13表达异常的基础。这些研究将大大促进我们对DNA甲基化在OA病理学中的重要性的理解。